Impact of Pasireotide on Postoperative Pancreatic Fistulas Following Distal Resections
Cuvinte cheie
Abstract
Descriere
In total, between 2000 and 2016 in our University Hospital there were 276 elective distal pancreatectomies performed. In this retrospective cohort study, we included 258 of those distal pancreatectomy patients in the database in to our analysis. Pasireotide was administered preoperatively to all patients undergoing distal pancreatic resection between July 2014 to April 2016, as a part of a new practice in our clinic. One patient received both pasireotide and octreotide, for whom drug delivery was stopped after one day, and who was ex-cluded from analysis. We also excluded nine patients because insufficient data were found. Seven patients were excluded because they were recruited to another clinical study.
In total, 47 patients (18%) received 900-ug pasireotide administered subcutaneously twice daily for a week or until discharged from the hospital. We analyzed separately 31 (12%) patients who re-ceived octreotide peri-operatively. All other 180 (70%) distal resection patients operated on beween 2000 and 2016 constituted the control group.
The drug used in this study, pasireotide (Signifor), was supplied by Novartis Europharm Ltd. (Novartis, Basel, Switzerland). The drug manufacturer did not take part in the study nor did it cover any costs.
We collected information about the patient age, gender, the American Society of Anesthesiologists (ASA) Physical Status Classification, tumor histology and grade and type of resection. In addition, we recorded postoperative information, the length of the hospital stay, fever following surgery (>38 °C), complications and surgical and other re-operations.
Datele
Ultima verificare: | 01/31/2020 |
Primul depus: | 02/18/2020 |
Inscriere estimată trimisă: | 02/20/2020 |
Prima postare: | 02/23/2020 |
Ultima actualizare trimisă: | 02/20/2020 |
Ultima actualizare postată: | 02/23/2020 |
Data actuală de începere a studiului: | 06/30/2014 |
Data estimată de finalizare primară: | 04/29/2016 |
Data estimată de finalizare a studiului: | 04/29/2016 |
Stare sau boală
Intervenție / tratament
Drug: Pasireotide
Fază
Grupuri de brațe
Braţ | Intervenție / tratament |
---|---|
Pasireotide Patients who received pasireotide perioperatively | Drug: Pasireotide 900-ug pasireotide administered subcutaneously twice daily for a week or until discharged from the hospital |
Octreotide Patients who received perioperative octreotide | |
Control Patients who received no additional medication in the timely cohort |
Criterii de eligibilitate
Vârste eligibile pentru studiu | 18 Years La 18 Years |
Sexe eligibile pentru studiu | All |
Metoda de eșantionare | Non-Probability Sample |
Acceptă voluntari sănătoși | da |
Criterii | Inclusion Criteria: All distal pancreatic resection patients in our time frame Exclusion Criteria: Included in another clinical trial, received both medications, inadequite patient records |
Rezultat
Măsuri de rezultate primare
1. CR-POPF [90 days]
Măsuri de rezultate secundare
1. Postpancreatectomy complication [90 days]